References
- Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic endocrine tumours. Lancet Oncol 2008;9:61–72.
- Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909–18.
- Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012;95:74–87.
- Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrineneoplasms of the digestive system. In: Bosman FT, et al., editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC press; 2010. pp13-4
- Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005;19:659–73.
- Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of proton pump inhibitor. Aliment Pharmacol Ther 2012;36:644–9.
- Jianu CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012;47:64–7.
- Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001;13:1449–56.
- Annibale B, Marignani M, Azzoni C, et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57–64.
- Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1998;41:185–200.
- Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008;93:1582–91.
- Bordi C, Corleto VD, Azzoni C, et al. The antral mucosa as a new site for endocrine tumors in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndromes. J Clin Endocrinol Metab 2001;86:2236–42.
- Merola E, Sbrozzi Vanni A, Panzuto F, et al.Type I. Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate. Neuroendocrinology 2011;95:207–13.
- Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990;4:131–8.
- Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209–18.
- Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012;46:397–400.
- Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 2012;35:165–74.
- Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 2009;15:1–16.
- Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36:959–71.
- Rindi G, Azioni C, La Rosa S, Klersy C, Parlotti D, Rappel S, et al.L cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532–41.